Notwithstanding various setbacks, various MDM2 inhibitors have now progressed into late-phase clinical development. New tactics have also been produced to enhance the efficacy of MDM2 inhibitors and to mitigate their on-focus on toxicity. Within this review, we summarize the development and challenges in the development of a MDM2 specific therapy. https://landenoomfg.blogspothub.com/31009056/the-fact-about-squalene-that-no-one-is-suggesting